Niche Biopharmaceuticals LLC — SEC Form D Filing

Niche Biopharmaceuticals LLC filed an SEC Form D on May 11, 2026, reporting $200K raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
May 11, 2026
Amount reported
$200K
Round stage
Seed
Industry
Pharmaceuticals
Website
https://nichebiopharma.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Atopic dermatitis is a focus area due to its prevalence and the inadequacy of current treatments, as there is a large market indicating unmet needs.

Solution

Niche Biopharmaceuticals is developing a Coupled Anti-infected Immunomodulatory Therapeutic (CAIT), effective against bacteria and viruses, which is also anti-inflammatory and resistant to bacterial resistance.

Why now

There is a growing need for effective treatments for antibiotic-resistant infections and viral diseases, making this an opportune moment for innovative solutions.

Verdict

Investors said yes at this moment due to the urgent need for innovative treatments in the face of growing antibiotic resistance, implicitly betting on the belief that this unique combination therapy could fill a critical void in the market. This cleared because of the pressing healthcare landscape, not because of a clear path to profitability. The limited upside lies in the nascent stage of drug development and the unpredictable hurdles of regulatory approvals, suggesting a long timeline before any return on investment.

Source: SEC EDGAR Form D filing